Ibrutinib,Tisagenlecleucel,venetoclax
abbvie,janssen,roche,novartis
['mantle,(-dismantle)', 'venetoclax', ' ibru', 'tisa-cel', 'lymphoma', 'lymsm']
 presents our sponsored iit of time-limited ibrutinib and tisa-cel (car-t) for #mantle cell #lymphoma. well-tolerated, high cr-rate, overcame resistance mutations that bcl2i (eg venetoclax) might address. #lymsm #ash2022 #ash22 
Clinical haematologist at Peter MacCallum Cancer Centre in Melbourne. Aggressive Lymphoma Lead. MDS/AML/myeloma.Early phase trials. Views are my own.